209 related articles for article (PubMed ID: 11130727)
1. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase.
Lay AJ; Jiang XM; Kisker O; Flynn E; Underwood A; Condron R; Hogg PJ
Nature; 2000 Dec; 408(6814):869-73. PubMed ID: 11130727
[TBL] [Abstract][Full Text] [Related]
2. Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin.
Stathakis P; Lay AJ; Fitzgerald M; Schlieker C; Matthias LJ; Hogg PJ
J Biol Chem; 1999 Mar; 274(13):8910-6. PubMed ID: 10085135
[TBL] [Abstract][Full Text] [Related]
3. Biological regulation through protein disulfide bond cleavage.
Hogg PJ
Redox Rep; 2002; 7(2):71-7. PubMed ID: 12189052
[TBL] [Abstract][Full Text] [Related]
4. Measurement of reduction of disulfide bonds in plasmin by phosphoglycerate kinase.
Lay AJ; Hogg PJ
Methods Enzymol; 2002; 348():87-92. PubMed ID: 11885297
[No Abstract] [Full Text] [Related]
5. Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action.
Sharma MR; Rothman V; Tuszynski GP; Sharma MC
Exp Mol Pathol; 2006 Oct; 81(2):136-45. PubMed ID: 16643891
[TBL] [Abstract][Full Text] [Related]
6. Mutation of human plasminogen kringle 1-5 enhances anti-angiogenic action via increased interaction with integrin alpha(v)beta(3).
Chang PC; Chang YJ; Wu HL; Chang CW; Lin CI; Wang WC; Shi GY
Thromb Haemost; 2008 Apr; 99(4):729-38. PubMed ID: 18392331
[TBL] [Abstract][Full Text] [Related]
7. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis.
Cao R; Wu HL; Veitonmäki N; Linden P; Farnebo J; Shi GY; Cao Y
Proc Natl Acad Sci U S A; 1999 May; 96(10):5728-33. PubMed ID: 10318952
[TBL] [Abstract][Full Text] [Related]
8. Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesis.
Wang H; Doll JA; Jiang K; Cundiff DL; Czarnecki JS; Wilson M; Ridge KM; Soff GA
Cancer Res; 2006 Jul; 66(14):7211-5. PubMed ID: 16849568
[TBL] [Abstract][Full Text] [Related]
9. A sandwich ELISA for phosphoglycerate kinase.
Zhao W; Pao S; Malik F; Soh J; Fernandez S; Chirico WJ
J Immunoassay Immunochem; 2008; 29(3):220-33. PubMed ID: 18569371
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a reduced form of plasma plasminogen as the precursor for angiostatin formation.
Butera D; Wind T; Lay AJ; Beck J; Castellino FJ; Hogg PJ
J Biol Chem; 2014 Jan; 289(5):2992-3000. PubMed ID: 24338014
[TBL] [Abstract][Full Text] [Related]
11. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen.
Heidtmann HH; Nettelbeck DM; Mingels A; Jäger R; Welker HG; Kontermann RE
Br J Cancer; 1999 Dec; 81(8):1269-73. PubMed ID: 10604721
[TBL] [Abstract][Full Text] [Related]
12. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells.
Stathakis P; Fitzgerald M; Matthias LJ; Chesterman CN; Hogg PJ
J Biol Chem; 1997 Aug; 272(33):20641-5. PubMed ID: 9252380
[TBL] [Abstract][Full Text] [Related]
13. Macrophage formation of angiostatin during inflammation. A byproduct of the activation of plasminogen.
Falcone DJ; Khan KM; Layne T; Fernandes L
J Biol Chem; 1998 Nov; 273(47):31480-5. PubMed ID: 9813061
[TBL] [Abstract][Full Text] [Related]
14. Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases.
Daly EB; Wind T; Jiang XM; Sun L; Hogg PJ
Biochim Biophys Acta; 2004 Apr; 1691(1):17-22. PubMed ID: 15053920
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis.
Hajitou A; Sounni NE; Devy L; Grignet-Debrus C; Lewalle JM; Li H; Deroanne CF; Lu H; Colige A; Nusgens BV; Frankenne F; Maron A; Yeh P; Perricaudet M; Chang Y; Soria C; Calberg-Bacq CM; Foidart JM; Noël A
Cancer Res; 2001 Apr; 61(8):3450-7. PubMed ID: 11309307
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene.
Ishikawa H; Nakao K; Matsumoto K; Ichikawa T; Hamasaki K; Nakata K; Eguchi K
Hepatology; 2003 Mar; 37(3):696-704. PubMed ID: 12601367
[TBL] [Abstract][Full Text] [Related]
17. Generation of multiple angiogenesis inhibitors by human pancreatic cancer.
Kisker O; Onizuka S; Banyard J; Komiyama T; Becker CM; Achilles EG; Barnes CM; O'Reilly MS; Folkman J; Pirie-Shepherd SR
Cancer Res; 2001 Oct; 61(19):7298-304. PubMed ID: 11585769
[TBL] [Abstract][Full Text] [Related]
18. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis.
Pozzi A; LeVine WF; Gardner HA
Oncogene; 2002 Jan; 21(2):272-81. PubMed ID: 11803470
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression.
Sharma MR; Koltowski L; Ownbey RT; Tuszynski GP; Sharma MC
Exp Mol Pathol; 2006 Oct; 81(2):146-56. PubMed ID: 16643892
[TBL] [Abstract][Full Text] [Related]
20. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2.
Oh HK; Ha JM; O E; Lee BH; Lee SK; Shim BS; Hong YK; Joe YA
Cancer Res; 2007 May; 67(10):4851-9. PubMed ID: 17510415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
